<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 12 Apr 2021 19:19:47 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>AACR重磅：PROTAC分子 ARV-110 、ARV-471结构公布</title><link>https://mp.weixin.qq.com/s/C03-ranwU03Yl7mxdGpNiQ</link><description></description><content:encoded><![CDATA[AACR重磅：PROTAC分子 ARV-110 、ARV-471结构公布]]></content:encoded><pubDate>Mon, 12 Apr 2021 18:33:34 +0800</pubDate></item><item><title>直播预告 | 2021 AACR研发投资新机会</title><link>https://mp.weixin.qq.com/s/mDddCKqOyfbbSqDfMoHG3A</link><description></description><content:encoded><![CDATA[直播预告 | 2021 AACR研发投资新机会]]></content:encoded><pubDate>Mon, 12 Apr 2021 18:33:34 +0800</pubDate></item><item><title>国家知识产权局：苹果酸舒尼替尼晶型专利全部无效</title><link>https://mp.weixin.qq.com/s/pOVUKUbAJvCYEg6O2BKDHg</link><description></description><content:encoded><![CDATA[国家知识产权局：苹果酸舒尼替尼晶型专利全部无效]]></content:encoded><pubDate>Mon, 12 Apr 2021 18:33:34 +0800</pubDate></item><item><title>康宁杰瑞在AACR 2021年会上公布KN046联合白蛋白紫杉醇治疗三阴乳腺癌的临床研究数据</title><link>https://mp.weixin.qq.com/s/uEEL2BH_AXDcQrtKH6BJyQ</link><description></description><content:encoded><![CDATA[康宁杰瑞在AACR 2021年会上公布KN046联合白蛋白紫杉醇治疗三阴乳腺癌的临床研究数据]]></content:encoded><pubDate>Mon, 12 Apr 2021 18:33:34 +0800</pubDate></item><item><title>新疆“2+4”联盟集采，约定采购量随企业降幅增加</title><link>https://mp.weixin.qq.com/s/txIcVrUfz4rgXihfqwho2w</link><description></description><content:encoded><![CDATA[新疆“2+4”联盟集采，约定采购量随企业降幅增加]]></content:encoded><pubDate>Mon, 12 Apr 2021 18:33:34 +0800</pubDate></item><item><title>盘点：这9款中国公司开发的创新药已在美国申报上市</title><link>https://mp.weixin.qq.com/s/2Ux5r-hBW6y6BLJd10FMHg</link><description></description><content:encoded><![CDATA[盘点：这9款中国公司开发的创新药已在美国申报上市]]></content:encoded><pubDate>Sat, 10 Apr 2021 09:29:06 +0800</pubDate></item><item><title>LAG-3 疗法获FDA快速通道资格，一线治疗头颈部鳞状细胞癌</title><link>https://mp.weixin.qq.com/s/dtWkssJptnDFPLYmc0fiig</link><description></description><content:encoded><![CDATA[LAG-3 疗法获FDA快速通道资格，一线治疗头颈部鳞状细胞癌]]></content:encoded><pubDate>Sat, 10 Apr 2021 09:29:06 +0800</pubDate></item><item><title>豪森「阿美替尼」拟纳入突破性疗法，一线治疗NSCLC</title><link>https://mp.weixin.qq.com/s/XUeqVBA9HOxfsoXFKMZJlA</link><description></description><content:encoded><![CDATA[豪森「阿美替尼」拟纳入突破性疗法，一线治疗NSCLC]]></content:encoded><pubDate>Sat, 10 Apr 2021 09:29:06 +0800</pubDate></item><item><title>第四批国采，8省已确定执行时间</title><link>https://mp.weixin.qq.com/s/TetwViTH0GtChISH6D6pXg</link><description></description><content:encoded><![CDATA[第四批国采，8省已确定执行时间]]></content:encoded><pubDate>Sat, 10 Apr 2021 09:29:06 +0800</pubDate></item><item><title>辉瑞BCMA/CD3双抗申报临床</title><link>https://mp.weixin.qq.com/s/bCrBQyvRLUZXyjcLGt5hkQ</link><description></description><content:encoded><![CDATA[辉瑞BCMA/CD3双抗申报临床]]></content:encoded><pubDate>Sat, 10 Apr 2021 09:29:06 +0800</pubDate></item><item><title>首个伊布替尼仿制药申报上市！原研2020年销售额94亿美元</title><link>https://mp.weixin.qq.com/s/OxcsbuLuaDjng-YdsRpZiw</link><description></description><content:encoded><![CDATA[首个伊布替尼仿制药申报上市！原研2020年销售额94亿美元]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>基石药业「普拉替尼胶囊」新适应症上市申请拟纳入优先审评</title><link>https://mp.weixin.qq.com/s/ZyUAitOlkN4x0NB6RIWetA</link><description></description><content:encoded><![CDATA[基石药业「普拉替尼胶囊」新适应症上市申请拟纳入优先审评]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>国内企业首家——朗来科技P2X3受体选择性拮抗剂临床申请正式受理</title><link>https://mp.weixin.qq.com/s/WXJv3URhHH-lGeKkoQ8MMw</link><description></description><content:encoded><![CDATA[国内企业首家——朗来科技P2X3受体选择性拮抗剂临床申请正式受理]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>国内首个CD70抗体药物申报临床</title><link>https://mp.weixin.qq.com/s/ssLOz2ZTx-GjgvVvSlw7pw</link><description></description><content:encoded><![CDATA[国内首个CD70抗体药物申报临床]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>新疆牵头省际集采来袭，10品种开启报量</title><link>https://mp.weixin.qq.com/s/4itXT2g1Y-H_ZbOd_w56bg</link><description></description><content:encoded><![CDATA[新疆牵头省际集采来袭，10品种开启报量]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>Opdivo联合疗法治疗食管鳞癌III期研究成功</title><link>https://mp.weixin.qq.com/s/QHmN9pNZIC7pFaHcApdB-w</link><description></description><content:encoded><![CDATA[Opdivo联合疗法治疗食管鳞癌III期研究成功]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>Keytruda单药辅助治疗肾细胞癌III期研究成功</title><link>https://mp.weixin.qq.com/s/0Gpc2fdJp5npGSqwcQGqbA</link><description></description><content:encoded><![CDATA[Keytruda单药辅助治疗肾细胞癌III期研究成功]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>NSCLC术后辅助治疗！奥希替尼新适应症获批</title><link>https://mp.weixin.qq.com/s/MA5-GP-bgO9BYB_7Q27Ztw</link><description></description><content:encoded><![CDATA[NSCLC术后辅助治疗！奥希替尼新适应症获批]]></content:encoded><pubDate>Thu, 08 Apr 2021 09:31:00 +0800</pubDate></item><item><title>特瑞普利单抗第3项适应症获批！治疗尿路上皮癌</title><link>https://mp.weixin.qq.com/s/RZe7xABa2E8REctuH6ir-Q</link><description></description><content:encoded><![CDATA[特瑞普利单抗第3项适应症获批！治疗尿路上皮癌]]></content:encoded><pubDate>Thu, 08 Apr 2021 09:31:00 +0800</pubDate></item><item><title>武田「醋酸艾替班特注射液」在华获批上市</title><link>https://mp.weixin.qq.com/s/BR7EQbxNWTJxpAuLY_jnIQ</link><description></description><content:encoded><![CDATA[武田「醋酸艾替班特注射液」在华获批上市]]></content:encoded><pubDate>Thu, 08 Apr 2021 09:31:00 +0800</pubDate></item></channel></rss>